Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuroMetrix settles investigation with $3.7m costs

This article was originally published in Clinica

Executive Summary

NeuroMetrix has agreed to pay $3.7m in order to settle a legal dispute over the sales and marketing of one its diagnostic tests for nerve conditions. The US Department of Justice (DOJ) and the Office of Inspector General (OIG) of the US Department of Health and Human Services alleged that NeuroMetrix offered payments to physicians to promote the use of its NC-stat system. The Waltham, Massachusetts-based company agreed to pay a $1.2m criminal penalty and observe the terms of a three-year deferred prosecution deal in return for the DoJ dropping the charges. In addition, the firm has paid $2.5m to settle further allegations that it had caused doctors to improperly bill the government for higher reimbursement payments. NeuroMetrix, which has not admitted to any of the billing charges, has entered into a five-year Corporate Integrity Agreement with the OIG as part of the settlement.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel